News
Video
Author(s):
COMBI-AD (NCT01682083) evaluated dabrafenib plus trametinib for patients with BRAF-mutated AJCC-stage III melanoma, and here the final results for RFS, distant-metastasis-free survival and overall survival are presented.
FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma
FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma
CSCC Experts Discuss Considerations for Determining Resectable Disease and Translating Data Into Practice
Revisit Every OncLive On Air Episode From August 2024
Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC
Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma
Dr Seymour on the Role of Mutational Profiling in CLL
Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features
Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL